BEUDAMED
    FDA Adverse Event Injury Summary report: N

    BIOFLO VORTEX

    MDR report key: 20549268 · Received October 28, 2024

    Report

    Report Number
    1317056-2024-00205
    Event Type
    Injury
    Date Received
    October 28, 2024
    Date of Event
    November 18, 2023
    Report Date
    November 26, 2024
    Manufacturer
    ANGIODYNAMICS, INC
    Product Code
    LJT
    UDI-DI
    H787CT80LPPDVI0
    PMA / PMN Number
    K190559
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    KY, US
    Reporter Occupation
    003

    Narratives

    Additional Manufacturer Narrative · 0

    THE REPORTED DEVICE IS NOT AVAILABLE TO BE RETURNED TO THE MANUFACTURER FOR EVALUATION. AN INVESTIGATION INTO THE ROOT CAUSE FOR THE EVENT IS CURRENTLY IN PROGRESS. THE RESULTS OF THE INVESTIGATION WILL BE SENT VIA A FOLLOW UP MEDWATCH. REFERENCE (B)(4).

    Additional Manufacturer Narrative · 0

    THE CUSTOMER'S REPORTED COMPLAINT DESCRIPTION OF PATIENT INFECTION CANNOT BE CONFIRMED GIVEN THE PATIENT CENTRIC NATURE OF THIS SERIOUS ADVERSE EVENT (SAE). NO PORT DEVICE WAS RETURNED FOR EVALUATION. IN ADDITION, THERE WAS NO REPORT OF PORT/CATHETER DEVICE MALFUNCTION, DAMAGE OR PERFORMANCE ISSUE DURING DEVICE USE. A DEVICE HISTORY RECORD (DHR) REVIEW OF THE INDICATED PACKAGING/ASSEMBLY/COMPONENT LOTS REVEALED NO QUALITY RELATED ISSUES OR MANUFACTURING DEFICIENCIES AT THE TIME OF MANUFACTURE. STERILIZATION LOAD RELEASE RECORDS FOR THE PACKAGING LOT WERE REVIEWED; WITH NO ISSUES OBSERVED. LABELING REVIEW: THE DIRECTIONS FOR USE (DFU) ITEM NUMBER 14600330-01 THAT IS PROVIDED IN THE REPORTED KIT CONTAINS THE FOLLOWING DIRECTIONS AND PRECAUTIONS: CONTRAINDICATIONS: PRESENCE OF INFECTION, BACTEREMIA, OR SEPTICEMIA. WARNINGS: THE DEVICE IS TO BE IMPLANTED, USED, MAINTAINED, AND REMOVED IN ACCORDANCE WITH INSTITUTIONAL AND/OR CENTERS FOR DISEASE CONTROL (CDC) GUIDELINES OR POLICIES CONTAMINATION OF THE DEVICE MAY LEAD TO INJURY, ILLNESS OR DEATH OF THE PATIENT PRECAUTIONS: CAREFULLY READ AND FOLLOW ALL INSTRUCTIONS PRIOR TO USE. AFTER IMPLANTATION OR ANY TREATMENT VIA THE PORT, THE SYSTEM SHOULD BE FLUSHED WITH NORMAL SALINE FOR INJECTION PER INSTITUTIONAL PROTOCOL. IF MORE THAN ONE DRUG IS TO BE ADMINISTERED, BETWEEN THE INDIVIDUAL DRUG APPLICATIONS, FLUSH THE SYSTEM WITH 5 TO 10 ML NORMAL SALINE FOR INJECTION TO PREVENT DRUG INTERACTION. AFTER ANY INFUSION, INJECTION OR BOLUS APPLICATION, THE SYSTEM SHOULD BE FLUSHED WITH EITHER NORMAL SALINE OR STERILE HEPARINIZED SALINE FOR INJECTION OR LOCKED WITH A HEPARIN SOLUTION PER INSTITUTIONAL PROTOCOL TO PREVENT THROMBOTIC OCCLUSION OF THE CATHETER. POTENTIAL COMPLICATIONS: BACTEREMIA, CATHETER THROMBOSIS, DEATH, INFLAMMATION, INFECTION, THROMBOEMBOLISM, THROMBOPHLEBITIS, TUNNEL INFECTION, VASCULAR THROMBOSIS. USE AND MAINTENANCE: TO HELP PREVENT CLOT FORMATION AND CATHETER BLOCKAGE, THE SMARTPORT+ OR SMARTPORT PLASTIC DEVICE SHOULD BE FILLED WITH STERILE HEPARINIZED SALINE AFTER EACH USE. IF THE PORT REMAINS UNUSED FOR LONG PERIODS OF TIME, THE LOCK SHOULD BE CHANGED AT LEAST ONCE EVERY FOUR WEEKS OR PER INSTITUTIONAL PROTOCOL PERFORM HAND HYGIENE BEFORE AND AFTER ALL VASCULAR ACCESS PROCEDURES. PREPARE SKIN WITH ANTISEPTIC SOLUTION PER INSTITUTIONAL PROTOCOL. ASEPTICALLY LOCATE AND ACCESS PORT INCLUDING USE OF STERILE GLOVES AND MASK PER THE NON-CORING HUBER NEEDLE DFU. ADD DRESSING AND STABILIZATION PER INSTITUTIONAL PROTOCOL. ASSESS THE ACCESS SITE, PORT FUNCTIONALITY, CHANGE DRESSING AND REPLACE NON-CORING NEEDLE PER INSTITUTIONAL PROTOCOLS. AFTER THERAPY COMPLETION, FLUSH PORT PER INSTITUTIONAL PROTOCOL. TO LOCK WITH HEPARIN, REPEAT WITH 5 ML 100 U/ML HEPARINIZED SALINE, OR WITH VOLUME CALCULATED ABOVE. CLOSE CLAMP WHILE INJECTING LAST 0.5 ML OF LOCK SOLUTION. WHEN THERAPY IS COMPLETE, REMOVE THE NON-CORING NEEDLE PER PRODUCT DFU AND COVER SITE ACCORDING TO INSTITUTIONAL PROTOCOL. A REVIEW OF THE ANGIODYNAMICS COMPLAINT SYSTEM NOTED NO ADVERSE TRENDS FOR THIS COMPLAINT TYPE AND PRODUCT FAMILY. THIS TYPE OF COMPLAINT WILL CONTINUE TO BE MONITORED FOR TRENDS. REFERENCE (B)(4).

    Description of Event or Problem · 0

    ON OR ABOUT (B)(6) 2023, PLAINTIFF UNDERWENT PLACEMENT OF AN ANGIODYNAMICS VORTEX PRODUCT, REFERENCE NUMBER (B)(4), LOT NUMBER 5767189. THE DEVICE WAS IMPLANTED BY DR.(B)(6), M.D., AT (B)(6) IN (B)(6), FOR THE PURPOSE OF ONGOING VEIN ACCESS. ON OR ABOUT (B)(6) 2023, PLAINTIFF PRESENTED TO (B)(6) HOSPITAL IN (B)(6), AFTER A HOME NURSE SWABBED HER PORT DUE TO TENDERNESS AT THE PORT SITE. BLOOD CULTURES TESTED POSITIVE FOR ACINETOBACTER. PLAINTIFF WAS SEEN AT (B)(6), WHERE ADDITIONAL BLOOD CULTURES WERE DRAWN AND WERE POSITIVE FOR PSEUDOMONAS PUTIDA. PLAINTIFF WAS DISCHARGED WITH ANTIBIOTICS. ON OR ABOUT (B)(6) 2023, PLAINTIFF RETURNED TO (B)(6), WHERE REPEAT BLOOD CULTURES WERE DRAWN AND WERE ONCE AGAIN POSITIVE. PLAINTIFF'S MEDICAL TEAM DETERMINED THAT THE PORT WAS THE SOURCE OF THE INFECTION AND THAT THE DEFECTIVE PORT NEEDED TO BE REMOVED. ON OR ABOUT (B)(6) 2023, PLAINTIFF'S DEFECTIVE PORT WAS REMOVED BY DR. DAVID TUNER, M.D., AT UK ALBERT B. CHANDLER HOSPITAL. AS A RESULT OF HAVING THE VORTEX IMPLANTED, PLAINTIFF HAS, ALLEGEDLY, EXPERIENCED SIGNIFICANT MENTAL AND PHYSICAL PAIN AND SUFFERING, HAS SUSTAINED PERMANENT INJURY, PERMANENT AND SUBSTANTIAL PHYSICAL DEFORMITY, HAS UNDERGONE CORRECTIVE SURGERIES, AND HAS SUFFERED FINANCIAL OR ECONOMIC LOSS, INCLUDING, BUT NOT LIMITED TO, OBLIGATIONS FOR MEDICAL SERVICES AND EXPENSES, AND PRESENT AND FUTURE LOST WAGES.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1965449 BIOFLO VORTEX PORT & CATHETER, IMPLANTED, SUBCUTANEOUS, INTRAVASCULAR LJT ANGIODYNAMICS, INC CT80LPPDVI 5767189 H787CT80LPPDVI0

    Patients

    Seq Age Sex Outcome Treatment
    1 NA Unknown Hospitalization| O| R